The UCSF luminary and recipient of the prestigious award has played a pivotal part in identifying the cause of multiple sclerosis, leading to a new generation of game-changing therapies.
Local News Matters on MSN4h
UC San Francisco researcher wins Breakthrough Prize for multiple sclerosis discoveryA researcher at the University of California, San Francisco was honored for transforming the understanding and treatment of ...
The actress boosts awareness of MS as the West Hollywood-based neurologist works to limit its effect on patients ...
A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with ...
Researchers had known that there was something odd about the development of MS, and attributed it to the so-called hygiene ...
An American neurologist and an Italian epidemiologist whose work revolutionized the treatment of multiple sclerosis on ...
Treatment with tolebrutinib led to greater confirmed disability improvement at 6 months compared with placebo in patients ...
Genzyme Corp. (Sanofi Genzyme) has divulged emopamil-binding protein (EBP) inhibitors reported to be useful for the treatment of multiple sclerosis, transverse myelitis, neuromyelitis optica, optic ...
We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where ...
Learn more about whether Corcept Therapeutics Incorporated or Sanofi is a better investment based on AAII's A+ Investor ...
About This EventSanofi (Nasdaq: SNY) with We Are ILL, Inc., visits the Nasdaq MarketSite in Times Square. A patient advocacy organization, We Are ILL redefines what “sick” looks like by making the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback